NASDAQ:EQ
Equillium Inc. Stock News
$1.56
+0.0200 (+1.30%)
At Close: May 17, 2024
What This FDA Update Means for Equillium's COVID-19 Study
10:36am, Friday, 30'th Oct 2020
Equillium Inc. (NASDAQ: EQ) shares jumped on Friday after the company announced a key update from the U.S.
Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial
04:13pm, Thursday, 29'th Oct 2020
Equillium p lans to initiate global Phase 3 COVID-19 trial – EQUINOX – during Q4 2020
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
12:00am, Wednesday, 19'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Avenue Therapeutics Inc (NASDAQ: ATXI)
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI)
DarioHealth Corp (NASDAQ:...
Equillium Announces Closing of Public Offering of Common Stock
08:05pm, Tuesday, 18'th Aug 2020
LA JOLLA, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, to
Equillium Announces Pricing of Public Offering of Common Stock
01:42am, Friday, 14'th Aug 2020
LA JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, to
Equillium Announces Proposed Public Offering of Common Stock
08:02pm, Thursday, 13'th Aug 2020
LA JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, to
Equillium Reports Second Quarter 2020 Financial Results and Recent Highlights
12:37pm, Wednesday, 12'th Aug 2020
LA JOLLA, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, to
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) * Allovir Inc (NASDAQ: ALVR) * BioLife Solutions Inc (NASDAQ: BLFS) * BioSpecifics Technologies Corp. (NASDAQ: BSTC) (reacted to sec
What Type Of Shareholders Make Up Equillium, Inc.'s (NASDAQ:EQ) Share Registry?
12:00pm, Tuesday, 11'th Aug 2020
If you want to know who really controls Equillium, Inc. (NASDAQ:EQ), then you'll have to look at the makeup of its...
What Type Of Shareholders Own The Most Number of Equillium, Inc. (NASDAQ:EQ) Shares?
11:51am, Tuesday, 11'th Aug 2020
A look at the shareholders of Equillium, Inc. (NASDAQ:EQ) can tell us which group is most powerful. Institutions will...
Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study
08:07pm, Monday, 10'th Aug 2020
Complete response observed in five of seven patients in first two dose cohorts COVID-19 Pre-IND meeting request and briefing package submitted to the FDALA JOLLA, Calif., Aug. 10, 2020 (GLOBE NEWSWIR
With Biotech Stocks, Investors Love the Thrill of the Chase
09:30am, Wednesday, 05'th Aug 2020
Individual investors are placing their bets on biotech companies pursuing coronavirus advances. Some invest for fun and profit, while others want to be a part of a historic breakthrough.
Equillium to Present at BTIG Virtual Biotechnology Conference 2020
08:07pm, Thursday, 30'th Jul 2020
LA JOLLA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to tre
Southern California Bancorp Announces Results for the Second Quarter 2020
12:00am, Monday, 27'th Jul 2020
Southern California Bancorp (the “Company”) (OTC Pink: BCAL), the holding company for Bank of Southern California, N.A. (the “Bank”) today reported re
Zacks: Analysts Anticipate Equillium (NYSE:EQ) to Announce -$0.44 Earnings Per Share
02:44pm, Thursday, 16'th Jul 2020
Wall Street analysts expect Equillium (NYSE:EQ) to announce ($0.44) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Equilliu
